





[12,13,37].

[9,34].

[27].

[8, 23].

[38, 48, 49].

[16, 22].

*Wedelia chinensis*,

[32].

LNCaP

[39].

*in vivo*

[10].

(MMP) [15, 17].

[15, 24, 31, 45].

[49].

2.

2. . . **In vitro**

HaCaT) ( HFK2, ( SHEP WAC2)

[48,49].

27 o *Citrus*

[16, 22].

40 /

[28].

IC50

3.1 549 IC50 2.3

B16 4A5 IC50 2.0

T- CCRF-

HSB-2, IC50 1.3 TGBC11TKB.

[27].

4,4 '-

CEM-1 CEM-

(P 388 ), IC50 (1 ) [22, 26].

10 [14]. IC50 (25 ), (41 )

(27 ), (68 M).

(

IC5o 1 [30].

[29]

(PC 3)



2 569  
 2 588  
 (OR: 0.81, p = 0.02),  
 (OR: 0.80; p = 0.06).

40% -  
 p- = 0.01).  
 34% -  
 (OR: 0.66 (0.49-0.91))

[11].

1.

820  
 1 548

13 %

0.5  
 [40].

2.

EGCG,

1 434

c

Long Island,

1 440

[13],

(OR: 0.54),  
 3- (OR: 0.74)

(OR 0.61: (0.45, 0.83)),  
 (OR 0.69) [20].

5

66 940

[21].

3.

347

1984 2002

6.

1.

[ ]- : 2008.-232

7.

2.

65-74

2/3.- 7-18.

« » / . 2005.-

8. Antognoni F. Induction of flavonoid production by UV-B radiation in *Passiflora quadrangularis* callus cultures / F. Antognoni, S. Zheng, C. Pagnucco [et al.] // *Fitoter.*, 2007.- Vol. 78.-P. 345-352.

3.

1.- 18..

9. Arbiser J.L. Reactive oxygen generated by Noxl triggers the angiogenic switch / J.L. Arbiser, J. Petros, R. Klafter[et al.]//*Proc. Natl. Acad. Sci. USA*, 2002,-Vol. 99.-P., 715-720.

4.

5.

.- 1998.- 2-3.- 44.

10. Bagli E. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activ-ity / E. Bagli, M. Stefaniotou, L. Morbidelli [et al.]//*Cancer Res.*. 2004.-Vol. 64.-P. 7936-7946.

: 2007.- 763

11. Bosetti C. Flavonoids and breast cancer risk in Italy n., *Cancer Epidemiol. Biomarkers Prev*/C. Bosetti, L. Spertini, M. Parpinel [et al.] - 2005.- Vol. 14.-P. 805-808.
12. Chen J.C. Effects of luteolin on arylamine N-acetyltransferase activity in human liver tumour cells /J.C. Chen, J.G. Chung, K.M. Lin //Cytobios .2000.- Vol.102.- P. 95-106.
13. Chen L. Cancer preventive effects of the green tea polyphenol (-)-epigallocatechin-3-gallate / L. Chen, H.-Y. Zhuang//Molecules 2007.- Vol. 12.- P. 946-957.
14. Cherng J.M. Chemopreventive effects of minor dietary constituents in common foods on human cancer cells /J.M. Cherng, D.E. Shieh, W. Chiang [et al.]//Biosci. Biotechnol. Biochem. 2007.-Vol. 71.-P. 1500-1504.
15. Chiang C.T. Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21(WAF1/CIP1) expression with rapamycin / C.T. Chiang, T.D. Way, J.K. Lin//Mol. Cancer Ther. 2007.- Vol. 6.-P. 2127-2138.
16. Chiu F.X. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells an xenografts / F.X. Chiu, J.K. Lin //Prostate, 2008.-Vol. 68.-P. 61-71.
17. Christofori G. New signals from the invasive front/ G. Christofori//Nature, 2006.-Vol. 441.-P.444-450.
18. Du G.J. Luteolin as a glycolysis inhibitor offers superior efficacy and lesser toxicity of doxorubicin in breast cancer cells / G.J. Du, Z.H. Song, H.H. Lin [et al.] // Biochem. Biophys. Res. Commun., 2008.-Vol. 372.-P. 497-502.
19. Fang J. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells /J. Fang, Q. Zhou, X.L. Shi [et al.]//Carcinogenesis 2007.-Vol. 28.-P. 713-723.
20. Fink B.N. Fruits, vegetables, and micronutrient intake in relation to breast cancer survival/B.N. Fink, M.M. Gaudet, J.A. Britton [et al.]//Bredst Cancer Res. Treat. 2006.-Vol. 98.- P. 199-208.
21. Gates M.A. A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer / M.A. Gates, S.S. Tworoger, J.L. Hecht [et al.] //Int. J. Cancer 2007.-Vol. 121.- P. 2225-2232.
22. Han D.H. Relationship between estrogen receptor-binding and estrogenic activities of environmental estrogens and suppression by flavonoids / D.H. Han, M.S. Denison, R. Tachibana [et al.]//Biosci. Biotechnol. Biochem. 2002.-Vol. 66.-P. 1479-1487.
23. Harborne J.B. Advances in flavonoid research since 1992/J.B. Harborne, C.A. Williams//Phytochemistry, 2000.-Vol. 55.- P.481-504.
24. Horinaka M. Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells / M. Horinaka, T. Yoshida, T. Shiraishi [et al.]// Oncogene, 2005.-Vol. 24.-P., 7180-7189.
25. Horvathova K. Determination of free radical scavenging activity of quercetin, rutin, luteolin and apigenin in H2O2-treated human ML cells K562 /K. Horvathova, L. Novotny, D. Tothova [et al.]//Neoplasma 2004.-Vol. 57.-P. 395-399.
26. Huang Y.T., Hwang J.J., Lee P.P. Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A 431 cells overexpressing epidermal growth factor receptor / Y.T. Huang, J.J. Hwang, P.P. Lee [et al.]// Br. J. Pharmacol. 1999.-Vol. 128.-P. 999-1010.
27. Jang S. Luteolin reduces 1L-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1 /S. Jang, K.W. Kelley, R.W. Johnson //Proc. Natl. Acad. Sci. USA. 2008.-Vol. 105.-P. 7534-7539.
28. Kawaii S. Antiproliferative activity of flavonoids on several cancer cell lines /S. Kawaii, Y. Tomono, E. Katase [et al.]//Biosci. Biotechnol. Biochem. 1999.-Vol. 63.- P. , 896-899.
29. Knowles L.M. Flavonoids suppress androgen-independent human prostate tumor proliferation / L.M. Knowles, D.A. Zigrossi, R.A. Tauber [et al.]// Nutr Cancer 2000,-Vol. 38.-P., 116-122.
30. Ko W.G. Effects of luteolin on the inhibition of proliferation and induction of apoptosis in human myeloid leukaemia cells / W.G. Ko, T.H. Kang, S.J. Lee [et al.]// Phytother. Res. 2002,-Vol. 16.-P. 295-298.
31. Lee L.T. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells / L.T. Lee, Y.T. Huang, J.J. Hwang [et al.]// Anticancer Res., 2002,22, 1615-1627.
32. Lin F.M., Chen L.R., Lin E.H. Compounds from *Wedelia chinensis* synergistically suppress androgen activity and growth in prostate cancer cells / F.M. Lin, L.R. Chen, E.H. Lin [et al.]//Carcinogenesis, 2007.- Vol. 28 - P. 2521-2529.
33. Lopez-Lazaro M. Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy / M. Lopez-Lazaro //Cancer Lett., 2007,252, 1-8.
34. Lopez-Lazaro M. The Warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen? / M. Lopez-Lazaro //Anticancer Agents Med. Chem., 2008.-Vol. 8.- P. 305-312.
35. Manju V. Chemopreventive potential of luteolin during colon carcinogenesis induced by 1,2-dimethylhydrazine / V. Manju, N. Nalini //J. Biochem. 2005.-Vol. 54.-P. 268-275.
36. Manju V. Protective role of luteolin in 1,2-dimethylhydrazine induced experimental colon carcinogenesis / V. Manju, N. Nalini//Cell Biochem. Funct. 2007.-Vol. 25.-P. 189-194.
37. Mantovani, A. Cancer-related inflammation / A. Mantovani, P. Allavena, A. Sica [et al.]//Nature, 2008.-Vol. 454.-P. 436-44.
38. Nayak V. Protection of mouse bone marrow against radiation-induced chromosome damage and stem cell death by the ocimum flavonoids orientin and vicenin. Radial. Res. / V. Nayak, P.U. Devi -2005, 763,165-71.
39. Noroozi M. Effects of flavonoids and vitamin C on oxidative DNA damage to human lymphocytes /M. Noroozi, W.J. Angerson, M.E. Lean //Am. J. Nutr. 1998.-Vol. 67.- P. 1210-1218.
40. Peterson J. Flavonoid intake and breast cancer risk: a case—control study in Greece. /J. Peterson, P. Lagiou, E. Samoli [et al.]//Br. J. Cancer 2003.- Vol. 89.- P. 1255-1259.

41. Plaschke K. Composition comprising one or more flavonoids, method of obtaining such composition and use thereof as UV-absorbing agent / K. Plaschke // US Pat. 6409996 B1, 2002.

42. Post J.F. Growth inhibitory effects of bioflavonoids and related compounds on human leukemic CEM-C1 and CEM-Cz cells/J.F. Post, R.S. Varma//Cancer Lett. 1992.-Vol. 67.-P. 207-213.

43. Samy R.P. Anti-tumor promoting potential of luteolin against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats/R.P. Samy, P. Gopalakrishnakone, S. Ignacimuthu //Chem. Biol. Interact. 2006.-Vol.164.-P. 1-14.

44. Seelinger G. Anti-cancerogenic effects of the Flavonoid Luteolin / G. Seelinger, I. Merfort, U. Wolfle [et al.]/Molecules.-2008.-Vol. 13.-P. 2628-2651.

45. Selvendiran K. Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids / K. Selvendiran, H. Koga, T. Ueno [et al.]/ Cancer Res. 2006.-Vol. 66.-P. 4826-4834.

46. Shimoi K. Glucuronidase deconjugation in inflammation / K. Shimoi, T. Nakayama // Methods Enzymol. 2005.- Vol. 400.-P. 263-272.

47. Steffan B. Inhaltsstoffe aus Pflanzen der indonesischen Volksmedizin (Jamu): Isolierung, Identifizierung, und Charakterisierung der antioxidativen Eigenschaften. Doctoral thesis. Heinrich Heine Universitat: Diisseldorf, Germany, 2005.

48. Uma D.P. Protection against prenatal irradiation-induced genomic instability and its consequences in adult

mice by Ocimum flavonoids, orientin and vicenin / D.P. Uma, M. Satyamitra //Int. J. Radiat. Biol, 2004.-Vol. 80.-P. 653-662.

49. Xavier C.P.R. Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells / C.P.R. Xavier, C.F. Lima, A. Preto [et al.]/ Cancer Lett. 2009.-Vol. 281, N 2 -P. 162-170.

50. Yamashita N. Distinct mechanisms of DNA damage in apoptosis induced by quercetin and luteolin / N. Yamashita, S. Kawanishi//Free Radic. Res. 2000.-Vol. 33.- P. 623-633.

51. Ziyen L. Evaluation of the anti-inflammatory activity of luteolin in experimental animal models / L. Ziyen, Z. Yongmei, Z. Nan [et al.]/Planta medica.- 2007.- Vol. 73, N 3.- P. 221-226.

52. Wittemer S.M. Bioavailability and pharmacokinetics of caffeoylquinic acids and flavonoids after oral administration of Artichoke leaf extracts in humans / S.M. Wittemer et al. // Phytomedicine 2005, Vol. 12.-P. 28-38.

53. Woerdenbag H. Cytotoxicity of flavonoids and sesquiterpene lactones from arnica species against the GLC4 and the COLO 320 cell lines / H. Woerdenbag, I. Merfort, CM. Passreiter [et al.]/Planta Med. 1994.-Vol. 60.-P. 434-437.

54. van Zanden J.J. Structural requirements for the flavonoid-mediated modulation of glutathione S-transferase Pl-1 and GS-Xpump activity in MCF7 breast cancer cells / J.J. Zanden, L. Geraets, H.M. Wortelboer [et al.]/Biochem. Pharmacol. 2004.- Vol. 67.- P. 1607-1617.

615.32:547.814.5,

... C.I. !  
 .! ^  
 K K  
 4.  
 K i :  
 vivo, in vitro in  
 EK BE E  
 4.  
 K :

in vivo, in vitro  
 N.V. POPOVA, S.I. DIKHTYAREV,  
 V.I. LITVINENKO  
**MEDICINAL PROPERTIES OF LYUTEOLIN**  
**Report 4. Prospects of the use of**  
**lyuteolin for treatment of cancer**  
 Key words: lyuteolin, bioflavonoids,  
 medicinal preparations  
 The results of informative analysis  
 of the application of bioflavonoid lyuteolin  
 are presented in the article. Several  
 pharmacological effects are shown in the  
 experiments in vitro and in vivo, which  
 could explain the anticarcinogenic activity  
 of lyuteolin in treatment of different  
 types of cancer. That fact had the scientific  
 and practical interest for treatment of  
 cancer patients and testified the prospect of  
 application it as medications.